Literature DB >> 33415071

Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond.

Gina Keiffer1, Kimberly L Aderhold1, Neil D Palmisiano1.   

Abstract

Entities:  

Keywords:  FLT3; acute myeloid leukemia; first line; gilteritinib; midostaurin

Year:  2020        PMID： 33415071      PMCID： PMC7783448          DOI： 10.3389/fonc.2020.562219

Source DB:  PubMed          Journal:  Front Oncol        ISSN： 2234-943X            Impact factor:   6.244


× No keyword cloud information.
  19 in total

Review 1.  What FLT3 inhibitor holds the greatest promise?

Authors:  Richard M Stone
Journal:  Best Pract Res Clin Haematol       Date:  2018-09-20       Impact factor: 3.020

2.  Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

Authors:  Max Jan; Thomas M Snyder; M Ryan Corces-Zimmerman; Paresh Vyas; Irving L Weissman; Stephen R Quake; Ravindra Majeti
Journal:  Sci Transl Med       Date:  2012-08-29       Impact factor: 17.956

3.  The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.

Authors:  C Albers; H Leischner; M Verbeek; C Yu; A L Illert; C Peschel; N von Bubnoff; J Duyster
Journal:  Leukemia       Date:  2013-01-16       Impact factor: 11.528

Review 4.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

Review 5.  FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.

Authors:  Ahmad I Antar; Zaher K Otrock; Elias Jabbour; Mohamad Mohty; Ali Bazarbachi
Journal:  Leukemia       Date:  2020-01-09       Impact factor: 11.528

6.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.

Authors:  A B Williams; B Nguyen; L Li; P Brown; M Levis; D Leahy; D Small
Journal:  Leukemia       Date:  2012-07-13       Impact factor: 11.528

8.  Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.

Authors:  Jessica K Altman; James M Foran; Keith W Pratz; Denise Trone; Jorge E Cortes; Martin S Tallman
Journal:  Am J Hematol       Date:  2017-12-04       Impact factor: 10.047

Review 9.  Potential targeting of FLT3 acute myeloid leukemia.

Authors:  Alexander J Ambinder; Mark Levis
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

10.  Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Authors:  Alexander E Perl; Giovanni Martinelli; Jorge E Cortes; Andreas Neubauer; Ellin Berman; Stefania Paolini; Pau Montesinos; Maria R Baer; Richard A Larson; Celalettin Ustun; Francesco Fabbiano; Harry P Erba; Antonio Di Stasi; Robert Stuart; Rebecca Olin; Margaret Kasner; Fabio Ciceri; Wen-Chien Chou; Nikolai Podoltsev; Christian Recher; Hisayuki Yokoyama; Naoko Hosono; Sung-Soo Yoon; Je-Hwan Lee; Timothy Pardee; Amir T Fathi; Chaofeng Liu; Nahla Hasabou; Xuan Liu; Erkut Bahceci; Mark J Levis
Journal:  N Engl J Med       Date:  2019-10-31       Impact factor: 91.245
View more
  1 in total

Review 1.  In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge.

Authors:  Paulina Stefaniuk; Agnieszka Szymczyk; Monika Podhorecka
Journal:  J Clin Med       Date:  2022-07-23       Impact factor: 4.964
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.